Persistent Systems Limited has informed stock exchanges about an investor session conducted with Cusana Capital on March 18, 2026. The interaction was held in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Session Details

The investor session was conducted on a one-on-one basis in physical mode at 10:00 am IST. During this interaction, the company reiterated information that had been previously shared during its earnings call held on Tuesday, January 20, 2026.

Earnings Call Reference

The session focused on information from the earnings call for the quarter and nine months ended December 31, 2025. The company confirmed that no additional information beyond what was shared in the previous earnings presentation was disclosed during this investor interaction.

Regulatory Compliance

Persistent Systems has fulfilled its disclosure obligations by informing both the National Stock Exchange of India Limited and BSE Limited about the outcome of this investor session. The communication was signed by Company Secretary Amit Atre and submitted to ensure transparency with all stakeholders.

The company has provided a web-link to its investor presentation and factsheet for Q3 FY26, allowing investors to access the relevant financial information that was discussed during the session.

Persistent Systems has announced a strategic collaboration with NVIDIA to accelerate the development and deployment of AI-powered solutions for the Healthcare and Life Sciences industry. The partnership aims to help HLS organizations advance computational drug discovery and improve research outcomes using Generative AI and advanced analytics.

Strategic Collaboration Details

The collaboration addresses the increasing pressure on HLS organizations to drive innovation while operating in highly complex, regulated, and data-intensive environments. By combining Persistent's deep domain and engineering expertise with NVIDIA's full-stack AI platform, Life Sciences enterprises can transition from AI experimentation to real-world production deployments in mission-critical environments.

GenMolVS Solution Launch

Persistent has created the Generative Molecules and Virtual Screening (GenMolVS) solution, powered by the NVIDIA BioNeMo platform and NVIDIA NeMo Agent Toolkit. This solution delivers AI-driven molecular simulations that model the physical and chemical properties of molecules using large domain-specific models.

The GenMolVS solution creates intelligent agents to streamline real-time drug discovery workflows through:

• Agentic workflows enabling continuous decisioning across virtual screening
• Candidate prioritization for improved research outcomes
• Downstream experimental planning to guide laboratory experiments
• High-fidelity molecular simulation and virtual screening at scale

Technology Infrastructure and Capabilities

Persistent will leverage NVIDIA AI Enterprise for specialized Life Sciences R&D use cases, including preclinical research. The solution enables high-fidelity molecular simulation and virtual screening at scale, applying AI to model and reason real-world biological and chemical behavior before realization in wet laboratory environments.

The infrastructure includes NVIDIA accelerated computes, servers, NVIDIA AI Enterprise, and NVIDIA NIM microservices to expedite cost-effective development of applications with scalable options and highly accurate AI outputs embedded directly into enterprise workflows.

Industry Impact and Benefits

This simulation-led approach allows Life Sciences organizations to de-risk early-stage discovery, accelerate experimental cycles, and improve downstream success rates in clinical development pipelines. The collaboration enables BioPharma clients to move from months-long experiments to AI-driven discovery in days, using simulation-led intelligence to guide real-world experimentation without compromising scientific rigor or compliance.

Leadership Perspectives

Ganesh Nathella, Executive Vice President and General Manager - HLS Business at Persistent, emphasized that healthcare and life sciences organizations need to discover new therapies faster, as traditional R&D processes are too slow and labor-intensive. John Fanelli, Vice President - Enterprise Software at NVIDIA, highlighted the industry's rapid movement toward AI-driven computational research and discovery to meet urgent global demand for new therapies.

Through this collaboration, Persistent will expand its AI and LLM engineering capabilities by leveraging NVIDIA AI infrastructure, training resources, and certification programs to deliver increasingly sophisticated data and AI platforms for clients.